1011 Stock Overview
Engages in the investment, research and development, manufacturing, sales, and distribution of pharmaceutical products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
China NT Pharma Group Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.27 |
| 52 Week High | HK$1.40 |
| 52 Week Low | HK$0.17 |
| Beta | -1.37 |
| 1 Month Change | 6.00% |
| 3 Month Change | 10.88% |
| 1 Year Change | -61.03% |
| 3 Year Change | -62.14% |
| 5 Year Change | -82.57% |
| Change since IPO | -99.31% |
Recent News & Updates
Recent updates
A Look At The Intrinsic Value Of China NT Pharma Group Company Limited (HKG:1011)
Mar 06
China NT Pharma Group Company Limited's (HKG:1011) Price Is Right But Growth Is Lacking
Dec 29Estimating The Intrinsic Value Of China NT Pharma Group Company Limited (HKG:1011)
Oct 30Is China NT Pharma Group (HKG:1011) Using Too Much Debt?
Apr 13Shareholder Returns
| 1011 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -5.4% | -1.9% | -0.5% |
| 1Y | -61.0% | -3.9% | 19.9% |
Return vs Industry: 1011 underperformed the Hong Kong Pharmaceuticals industry which returned -3.9% over the past year.
Return vs Market: 1011 underperformed the Hong Kong Market which returned 19.9% over the past year.
Price Volatility
| 1011 volatility | |
|---|---|
| 1011 Average Weekly Movement | 21.3% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in HK Market | 18.6% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 1011's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1011's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 20 | David Ng | www.ntpharma.com |
China NT Pharma Group Company Limited, together with its subsidiaries, engages in the investment, research and development, manufacturing, sales, and distribution of pharmaceutical products in the People’s Republic of China. It manufactures, sells, and trades in prescription medicines; offers products in the tumor and blood system diseases, digestive system diseases, central nervous system diseases, diseases of respiratory system, and other therapeutic fields; and produces and sells NT branded products. The company also provides marketing and promotion services to suppliers, and logistics and consulting services.
China NT Pharma Group Company Limited Fundamentals Summary
| 1011 fundamental statistics | |
|---|---|
| Market cap | HK$69.98m |
| Earnings (TTM) | -HK$29.88m |
| Revenue (TTM) | HK$33.35m |
2.1x
P/S Ratio-2.3x
P/E RatioIs 1011 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1011 income statement (TTM) | |
|---|---|
| Revenue | CN¥31.30m |
| Cost of Revenue | CN¥25.59m |
| Gross Profit | CN¥5.71m |
| Other Expenses | CN¥33.74m |
| Earnings | -CN¥28.03m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 18.23% |
| Net Profit Margin | -89.57% |
| Debt/Equity Ratio | -102.8% |
How did 1011 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 05:31 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
China NT Pharma Group Company Limited is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| P. Ting | CGS International |
| Lewis Pang | Cinda International Research Limited |
| Sze Chuen Tam | Core Pacific -Yamaichi International (H.K.) Limited |